This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Congenital Lactase Deficiency / Congenital Alactasia선천성 젖당분해효소결핍

Contents and key points
ItemDetails
A. Classification codesICD-10: E73.0 (congenital lactase deficiency) | Special Copayment Reduction: V117 (ultra-rare disease, copayment exempt)
B. SynonymsCongenital alactasia, congenital lactase deficiency, CLD, LCT gene deficiency, congenital lactase deficiency, neonatal lactose intolerance
C. Adult onsetLikelihood of first onset in adulthood: extremely low — by definition, congenital lactase deficiency presents from birth (the neonatal period), as soon as breast milk or lactose-containing formula is fed. It is an entirely separate genetic disease from adult-type lactose intolerance (lactase non-persistence). It is never diagnosed in adulthood, but patients who were properly diagnosed and treated may survive into adulthood and continue management.
1. HistoryFirst reported in Finland in 1959 (Holzel et al.) → intensive case descriptions in Finland from 1966 onward → LCT gene variants identified in the 2000s → an ultra-rare disease with only about 40 cases reported worldwide to date.
2. CausesPathogenic variants of the LCT gene (2q21) prevent synthesis or cause loss of function of intestinal (small intestinal) lactase (lactase-phlorizin hydrolase, LPH). Lactose breakdown is completely blocked.
3. GeneticsAutosomal recessive. LCT gene 2q21.3. A founder variant was found in Finland. Various pathogenic variants: frameshift, nonsense, splicing, missense. Differs from the gene regulatory region (MCM6) of adult-type lactose intolerance.
4. General epidemiologyOnly about 40 cases reported worldwide. Relatively high frequency in Finland. Ultra-rare disease. Very few reported cases in Asia and Korea.
5. PathophysiologyLoss of LPH enzyme in the small intestinal brush border cells → lactose cannot be broken down → increased osmotic pressure in the small intestine (lactose accumulation) → osmotic diarrhea. Bacterial fermentation in the colon → gas, abdominal distension, acidic stools.
6. SymptomsFrom right after birth, explosive watery diarrhea, abdominal distension, abdominal pain, and vomiting with breast milk/lactose formula feeding. Dehydration, electrolyte abnormalities, malnutrition. Symptoms resolve immediately on a lactose-free diet.
7. SignsAcidic stools (pH <6), positive fecal reducing substances (Clinitest), low LPH activity on small intestinal biopsy. Normal small intestinal mucosal histology (distinguishes it from adult-type lactose intolerance). Dehydration, failure to gain weight.
8. ScreeningNot included in newborn screening. Severe diarrhea with breastfeeding right after birth → clinical suspicion → measure fecal pH and reducing substances, confirm response to lactose-free diet. Confirmed by LCT gene analysis.
9. DiagnosisFecal pH <6 + positive fecal reducing substances + confirmed response to lactose-free diet. Small intestinal biopsy + measurement of LPH enzyme activity. LCT gene analysis (confirmation). Lactose breath test is supplementary.
10. TreatmentA complete lactose-free diet is the only fundamental treatment. Neonates: use of special lactose-free formula. After growing up, complete restriction of dairy products. Calcium and vitamin D supplementation is essential. Fluid and electrolyte correction in the acute phase. Exogenous lactase (lactase enzyme capsules) may be used as an adjunct.
11. PrognosisNormal growth and development are possible with strict adherence to a lactose-free diet. Symptoms recur immediately on renewed lactose exposure. Risk of reduced bone density from long-term calcium and vitamin D deficiency. Adherence to dietary education determines prognosis.
12. PreventionGenetic counseling, prenatal diagnosis, immediate switch to lactose-free feeding upon clinical suspicion right after birth (severe diarrhea). Preparation before birth when there is a family history (having lactose-free formula on hand). Regular nutritional and bone density monitoring.
13. ReferencesHolzel A et al. Lancet. 1959 (PMID 13800996) … and 9 other papers

1. History

The first clinical description of congenital lactase deficiency (CLD) dates back to a paper published in Lancet in 1959 by Holzel et al. in the United Kingdom. They reported cases of neonates who developed severe watery diarrhea, dehydration, and weight loss as soon as breastfeeding began right after birth, with symptoms resolving immediately on a lactose-free diet. These cases first presented the new disease concept of congenital deficiency of the lactose-digesting enzyme and became an important milestone in the history of inherited metabolic diseases.

Subsequently, in the 1960s, CLD cases began to be reported intensively in Finland. Launiala, Perheentupa, and others in Finland diagnosed CLD in infants hospitalized with severe neonatal diarrhea and systematically described the clinical course and treatment response. The intensive case finding in Finland suggested that CLD occurs at a relatively high frequency in this population and raised the possibility of a founder mutation. Worldwide, however, CLD has remained a very rare disease, with only a few dozen cases reported worldwide over several decades.

The molecular cause of CLD was identified in the early 2000s. Kuokkanen et al. (2006) first identified pathogenic variants of the LCT gene in Finnish CLD patients, and subsequently various pathogenic LCT variants (frameshift, nonsense, splicing, missense) were reported in patients of various ethnicities. Molecular diagnosis of CLD helped clearly distinguish it from adult-type lactose intolerance (adult-type hypolactasia/lactase non-persistence). Adult-type lactose intolerance is a normal variant in which lactase expression decreases in adulthood due to regulatory polymorphisms in the MCM6 gene upstream of the LCT gene, a mechanism fundamentally different from CLD. To date, about 40 confirmed CLD cases have been reported in the literature worldwide, showing that this disease, along with BCAT2 deficiency, is one of the rarest inherited metabolic diseases.


2. Causes

The cause of congenital lactase deficiency (CLD) is the inability to synthesize, or complete loss of function of, the small intestinal brush border enzyme lactase-phlorizin hydrolase (LPH, EC 3.2.1.108) due to pathogenic variants of the LCT gene located on the long arm of chromosome 2 (2q21.3). The LCT gene spans about 55 kb and consists of 17 exons, encoding a precursor protein (prepeptide) of 1927 amino acids. After cleavage of the signal peptide and prosequence, mature LPH (~160 kDa) inserted into the brush border membrane of the small intestine is activated as a functional disaccharidase.

LPH is the only enzyme that hydrolyzes lactose into glucose and galactose at the small intestinal brush border membrane. It also has the function of breaking down phlorizin into glucose and phloretin, but what is clinically important is its lactose-digesting function. In CLD, there are pathogenic variants in both alleles of the LCT gene, so the LPH protein cannot be synthesized or its function is completely lost. This is fundamentally different from adult-type lactose intolerance (lactase non-persistence). Adult-type lactose intolerance is not a variant of the LCT gene itself but a normal variant phenotype in which lactase expression gradually decreases in adulthood due to regulatory polymorphisms (c.-13910C>T, c.-22018G>A, etc.) in the MCM6 gene located about 13.9 kb upstream of the LCT gene.

Pathogenic LCT variants associated with CLD include frameshift, nonsense, splice-site, and missense variants. A variant first found in Finnish patients (c.4170+1G>A, etc.) and various other unique variants have been reported in patients of European and Middle Eastern descent. Pathogenic variants cause loss of LPH function by interfering with synthesis of the enzyme protein itself (frameshift, nonsense), interfering with protein folding, processing, and membrane insertion (missense), or disrupting mRNA splicing (splicing variants).


3. Genetics

CLD follows an autosomal recessive mode of inheritance. Patients have pathogenic variants in both alleles of the LCT gene (homozygous or compound heterozygous), and each heterozygous carrier parent is clinically normal. The probability that a child born to carrier parents is affected is 25%. The LCT gene is located on the long arm of chromosome 2 (2q21.3), spans about 55 kb, and consists of 17 exons. Because the adult-type lactose intolerance-associated polymorphism (c.-13910C>T) in the adjacent MCM6 gene is at a gene location separate from CLD pathogenic variants, CLD patients may also have the adult-type lactose intolerance genotype, but clinically the congenital deficiency predominates.

Reported pathogenic LCT variants are diverse, and founder effects appear in certain ethnic groups. In Finland, c.4170+1G>A (a splicing variant) and the c.5387T>G (p.Leu1796Arg) missense variant have been frequently reported. A separate founder variant was also identified in cases reported from Central Europe (Slovakia). The number of variants reported worldwide is very small, so pathogenicity determination in clinical databases is limited. Genetic testing is performed with NGS-based rare gastrointestinal disease panels, WES, or WGS. In populations where a specific founder variant has been identified, Sanger sequencing or targeted variant analysis is also possible. Pathogenicity determination of identified variants follows ACMG criteria, and functional studies (measurement of LPH activity on small intestinal biopsy) are used as an adjunct to variant interpretation.


4. General epidemiology

Congenital lactase deficiency (CLD) is an extremely rare inherited metabolic disease, with only about 40~50 confirmed cases reported in the literature worldwide to date. Along with BCAT2 deficiency (HVLI), it is one of the rarest inherited gastrointestinal diseases currently known. The exact prevalence and incidence are difficult to estimate statistically because the number of cases is too small. Historically, the most cases have been reported in Finland, which is presumed to reflect a founder effect. Even in Finland, the national incidence is estimated not to exceed 1 in several hundred thousand births.

Besides Finland, sporadic cases have been reported in various regions, including the United Kingdom, Slovakia, Poland, Turkey, Iran, and Arabia. Cases may also be found in populations with high rates of consanguineous marriage (the Middle East, some Central Asian populations). Official reports from East Asia, including Korea, have not been confirmed to date or are extremely few, but this may be due not to the absence of the disease but to lack of diagnostic awareness or to cases dying without explanation from severe neonatal diarrhea. There is no sex difference, and it occurs equally in boys and girls. Because CLD presents from the neonatal period, it is a disease encountered in the neonatal intensive care unit (NICU).

It is important not to confuse CLD with common adult-type lactose intolerance (a normal variant phenotype occurring in about 65~70% of the world's population). Adult-type lactose intolerance is a normal physiological variant and is very common in East Asians, including Koreans (about 95~100%), but this is an evolutionarily normal phenomenon in which lactase expression decreases in adulthood, with a mechanism and clinical features entirely different from congenital deficiency.


5. Pathophysiology

In the normal small intestine, lactase-phlorizin hydrolase (LPH) is expressed at high density on the membrane surface of brush border enterocytes and hydrolyzes dietary lactose into glucose and galactose. The hydrolyzed monosaccharides are absorbed across the small intestinal epithelium by active transport (SGLT1, GLUT2). In CLD, LPH is not synthesized or is nonfunctional, so ingested lactose cannot be broken down at all in the small intestine.

When undigested lactose accumulates in the small intestinal lumen, two main pathophysiological consequences occur. First is the osmotic effect. Undigested lactose acts as an osmotically active solute that draws water into the small intestinal lumen, causing osmotic diarrhea. The increased water in the small intestinal lumen causes rapid transit of intestinal contents, characterizing explosive watery diarrhea. Second is bacterial fermentation in the colon. When unabsorbed lactose reaches the colon, it is fermented by the intestinal flora, producing organic acids (lactic acid, butyric acid, etc.), carbon dioxide, hydrogen, and methane gas. This causes abdominal distension, abdominal pain, and periumbilical cramps, and leads to acidic stools (feces pH <6) and gas production. Excessive production of organic acids can directly damage the intestinal epithelium, resulting in secondary impairment of intestinal function.

If this process continues in neonates, it progresses to severe dehydration, electrolyte imbalance (hyponatremia, hypokalemia, metabolic acidosis), failure to thrive, and malnutrition (marasmus). Without treatment, it can lead to death from life-threatening dehydration and malnutrition. Switching to a lactose-free diet removes lactose from the small intestine, so osmotic diarrhea and bacterial fermentation stop immediately and symptoms resolve quickly. This is why confirming the response to a lactose-free diet is a key criterion in the diagnosis of CLD.


6. Symptoms

Typically, CLD presents with symptoms right after birth, immediately from the first feeding of breast milk or lactose-containing formula. The timing of symptom onset is a very important clue for clinical diagnosis.

Diarrhea: The most prominent symptom; severe explosive watery diarrhea occurs right after feeding or within a few hours. The stools are watery, sour-smelling (acidic), and accompanied by considerable gas. Fecal pH is acidic, below 6, and the fecal reducing substances test is positive. Stool frequency often reaches 10 or more per day. If diarrhea continues, dehydration, hypovolemia, and electrolyte imbalance (hyponatremia, hypokalemia, metabolic acidosis) progress rapidly.

Abdominal distension and abdominal pain: Because of gas production in the small intestine and colon, abdominal distension and hyperactive bowel sounds are prominent. In infants, abdominal pain is expressed as irritability and excessive crying.

Vomiting: Vomiting may occur right after feeding.

Failure to gain weight and malnutrition: If lactose intake continues, nutrient absorption in the intestine is severely impaired, causing failure to gain weight, and if treatment is delayed it progresses to severe malnutrition (marasmus). In contrast, switching to lactose-free formula stops diarrhea immediately and normalizes weight gain. This dramatic dietary response is a decisive clue for the clinical diagnosis of CLD.

Resolution of symptoms after switching to a lactose-free diet: The most characteristic clinical finding of CLD is that diarrhea completely resolves within 24~48 hours of switching to a lactose-elimination diet, with recovery to general good health. Thereafter, if lactose is ingested again in any form, diarrhea recurs immediately. This pattern helps differentiate it from functional lactose intolerance (adult type), intestinal infections, and other malabsorption disorders.


7. Signs

Stool test findings: The simplest and fastest screening tests for CLD are fecal pH and reducing substances tests. Fecal pH <6: reflects the production of organic acids by bacterial fermentation. Normal neonatal fecal pH is 5~8, but when there is lactose malabsorption the pH falls markedly into the acidic range. Fecal reducing substances test (Clinitest tablet method): unabsorbed lactose and its breakdown products, monosaccharides, are detected. Reducing substances of 0.5% or more is the significant threshold. However, because small amounts of reducing substances can be detected even normally in breastfed neonates, caution is needed in interpretation. Measurement of fecal lactose concentration (enzymatic method or chromatography) is also useful for confirmation.

Small intestinal biopsy: The traditional confirmatory method. LPH enzyme activity is measured in jejunal biopsy specimens. In CLD patients, LPH activity is markedly reduced to less than 5% of normal. Importantly, small intestinal mucosal histology (villus height, crypt depth, epithelial cell structure) is normal. This is the key to distinguishing CLD from secondary causes of lactase deficiency (celiac disease, rotavirus enteritis, short bowel syndrome, etc.). In secondary causes, mucosal damage is present and villous atrophy and the like are observed. Currently, LCT gene analysis tends to replace small intestinal biopsy, but when interpretation of genetic analysis results is uncertain, enzyme activity measurement is used as an adjunct.

Systemic findings: Signs of dehydration (sunken eyes, rapid heart rate, dry mucous membranes, reduced skin turgor, reduced urine output), metabolic acidosis (rapid breathing, lethargy), and weight loss and growth failure are observed.


8. Screening

Newborn screening of the general population for congenital lactase deficiency (CLD) is currently not included in the standard program of any country. This is because of the extreme rarity of the disease and the lack of standardized MS/MS markers for newborn screening. However, there are simple tests for clinically suspecting and diagnosing CLD early.

CLD must be included in the differential diagnosis of any neonate who develops severe explosive watery diarrhea right after the first feeding (breast milk or regular formula) after birth. Tests available at the initial clinical screening stage are as follows. First, fecal pH measurement: pH <6 is a strongly suspicious finding. Second, the fecal reducing substances test (Clinitest): a positive result supports lactose malabsorption. Third, a therapeutic trial of lactose-free formula: dramatic resolution of diarrhea within 24~48 hours of replacing lactose-containing formula or breast milk with completely lactose-free formula (soy-based or special lactose-free formula) is the most important clinical screening indicator. When there is a family history (carrier parents, affected siblings), affected status can be preliminarily confirmed by prenatal LCT gene analysis, and lactose-free formula can be prepared for right after birth.


9. Diagnosis

Confirmation of CLD is made by combining clinical findings, biochemical tests, small intestinal biopsy enzyme testing, and molecular genetic testing. A stepwise approach is recommended. Step 1, clinical and biochemical suspicion: Severe watery diarrhea with breast milk/lactose formula feeding from right after birth. Fecal pH <6. Positive fecal reducing substances. Complete resolution of diarrhea within 24~48 hours of switching to lactose-free formula. Immediate recurrence on lactose re-exposure. Step 2, small intestinal biopsy: Markedly reduced LPH enzyme activity on jejunal biopsy (less than 5% of normal). Normal small intestinal mucosal histology (no villous atrophy or epithelial cell abnormalities). This is the decisive criterion for differentiating it from secondary lactase deficiency.

Step 3, LCT gene analysis: Pathogenic LCT gene variants are confirmed with an NGS-based gastrointestinal/malabsorption panel or WES. Identification of homozygous or compound heterozygous variants confirms the diagnosis. Segregation analysis of the variants is performed with parental testing, and carrier status is confirmed. If pathogenic variants in the LCT gene are hard to find, exon-level deletions are excluded with MLPA. Supplementary tests: The lactose tolerance test is not recommended in infants because of safety concerns, but in older children or adults it can be used to confirm the absence of a rise in blood glucose after a lactose load. The lactose breath test (hydrogen/methane breath analysis) can be used as an adjunct in older children or adults. Differential diagnosis: Differentiation is needed from secondary lactase deficiency due to rotavirus or norovirus enteritis (transient), celiac disease (gluten-induced enteropathy), galactosemia (congenital disorder of galactose metabolism), and glucose-galactose malabsorption.


10. Treatment

The fundamental treatment of congenital lactase deficiency (CLD) is a complete lactose-free diet, which to date is the only and reliably effective treatment strategy. Completely blocking lactose intake makes diarrhea resolve immediately and enables normal growth and development. Conversely, if lactose is included in the diet in any form, symptoms recur immediately, so strict continuity of dietary management is essential.

Diet in the neonatal period and infancy: Special completely lactose-free formula (lactose-free infant formula) is started immediately. There are two options. First, soy protein-based lactose-free formula (soy-based lactose-free formula): contains no lactose, but the possibility of soy protein allergy must be considered. Second, hydrolyzed protein-based lactose-free formula (extensively hydrolyzed lactose-free formula): used when the risk of protein allergy is low. Through this, breast milk with the lactose removed (enzymatic treatment to remove lactose from the mother's milk) is theoretically possible but difficult in practice. Because lactose is the main carbohydrate in breast milk, exclusive breastfeeding is impossible for infants with CLD. This fact must be clearly explained to the mother, and the switch to lactose-free formula must be supported immediately.

Diet during weaning and growth: During the weaning stage, lactose-free foods (vegetables, fruits, meat, lactose-free grains) are used. Dairy products (milk, cheese, yogurt, butter, and all other lactose-containing foods) are completely excluded. Ingredient lists on food labels are checked thoroughly to avoid hidden lactose (products containing lactose, milk solids, whey, or casein). Calcium and vitamin D supplementation: Excluding dairy products can lead to a serious shortage of calcium intake. Calcium supplements (calcium carbonate or calcium citrate) and vitamin D supplementation are essential in the long term. Bone density monitoring (DXA follow-up from childhood) is needed. Fluid and electrolyte correction in the acute phase: In acute dehydration episodes before diagnosis, oral or intravenous fluid and electrolyte correction is needed. If there is prolonged metabolic acidosis, sodium bicarbonate correction is performed. Exogenous lactase: Taking commercially available lactase enzyme capsules/tablets before meals can break down part of dietary lactose, but in CLD endogenous LPH is completely lost, so complete lactose digestion is not guaranteed, depending on the efficiency and dose of the exogenous lactase. Therefore, exogenous lactase is used as an adjunct, not a substitute for a strict lactose-free diet.


11. Prognosis

In patients with CLD, strict adherence to a complete lactose-free diet enables normal growth, normal development, and a near-normal life expectancy. Because this disease can in principle be fully controlled by dietary management alone, its intrinsic prognosis is relatively good compared with other inherited metabolic diseases. However, there are several important issues that threaten the prognosis.

First, acute complications due to delayed diagnosis. If CLD is not recognized right after birth and lactose exposure continues, severe dehydration, electrolyte imbalance, malnutrition, brain damage, and death can occur. Deaths due to delayed diagnosis have been recorded in some cases reported worldwide. This shows that early clinical recognition is decisive for prognosis. Second, continuity of dietary management. If foods containing lactose are eaten accidentally or intentionally, symptoms recur immediately. As social activities increase after school age, dietary management can become difficult, and the ability to read food labels and caution when eating out are important. Third, long-term calcium and vitamin D deficiency. Excluding dairy products carries a risk of reduced bone density (osteopenia/osteoporosis) due to insufficient calcium intake, which as a long-term complication increases the risk of fractures in adulthood. Calcium and vitamin D supplementation and periodic bone density testing are essential.


12. Prevention

Primary prevention of CLD is achieved through genetic counseling and family screening. When a CLD patient is identified in a family, the LCT gene carrier status of both parents is checked. When carrier parents conceive, whether the fetus carries LCT variants can be checked by chorionic villus sampling (CVS, 11~14 weeks of gestation) or amniocentesis (15~20 weeks of gestation). For a fetus confirmed to be affected, preparations are made to use lactose-free formula immediately after birth. Preimplantation genetic testing (PGT) is also technically possible.

Secondary prevention is an early switch to a lactose-free diet in confirmed or high-risk neonates. On clinical suspicion (severe diarrhea right after birth), fecal pH and reducing substances tests are performed promptly, and if suspicion is strong, the infant is switched immediately to lactose-free formula without waiting for confirmation to prevent dehydration and malnutrition. After confirmation, a long-term lactose-free diet plan is established with a dietitian, and parent and family education is provided. Daycare centers, schools, and medical institutions are notified of the CLD diagnosis and dietary restrictions to prevent situations of accidental lactose ingestion. Tertiary prevention is prevention of long-term complications and includes regular nutritional monitoring (calcium, vitamin D, 25-OH vitamin D levels), bone density testing (DXA follow-up in childhood, every 1~2 years in adulthood), and assessment of growth and development.


13. References

  1. Holzel A, et al. Defective lactose absorption causing malnutrition in infancy. Lancet. 1959;1(7 ):1126-1128. PMID: 13800996
  2. Kuokkanen M, et al. Mutations in the translated region of the lactase gene (LCT) underlie congenital lactase deficiency. Am J Hum Genet. 2006;78(2):339-344. PMID: 16358224
  3. Torniainen S, et al. Four novel mutations in the lactase gene (LCT) underlying congenital lactase deficiency (CLD). BMC Gastroenterol. 2009;9:8. PMC2635369.
  4. Diekmann L, et al. Congenital lactase deficiency: Identification of a new mutation. An Pediatr (Barc). 2015;83(3):218. PMID: 26183728
  5. Bodvarsdottir TB, et al. A novel mutation within the lactase gene (LCT): the first report of congenital lactase deficiency diagnosed in Central Europe. BMC Gastroenterol. 2015;15:88. PMC4515929.
  6. Heyman MB. Lactose intolerance in infants, children, and adolescents. Pediatrics. 2006;118(3):1279-1286. PMID: 16951027
  7. Swallow DM. Genetics of lactase persistence and lactose intolerance. Annu Rev Genet. 2003;37:197-219. PMID: 14616060
  8. Järvelä I, et al. Assignment of the locus for congenital lactase deficiency to 2q21, in the vicinity of but separate from the lactase-phlorizin hydrolase gene. Am J Hum Genet. 1998;63(4):1078-1085. PMID: 9758608
  9. Rasinpera H, et al. A genetic test which can be used to diagnose adult-type hypolactasia in children. Gut. 2004;53(11):1571-1576. PMID: 15479672
  10. Behrendt M, et al. Disaccharide digestion deficiencies of the small intestinal brush-border membrane. J Clin Biochem Nutr. 2007;40(1):36-48. PMID: 18437221